Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, The Connection Study, will be presented at the...
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2025, among other things, the following was resolved: ContactsStaffan...
In accordance with the agreement reached with the FDA on 19 December 2024, IBT has today submitted the Clinical Study Report (CSR) for ‘The Connection...
Message from CEO The US Food and Drug Administration (FDA) has granted IBP-9414 “Breakthrough Therapy Designation.” This means that the FDA...
Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, “The Connection Study,” will be presented...
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice of the Annual General Meeting to be...
The U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy designation for IBP-9414’s potential to reduce gastrointestinal-related...
The Annual Report including Corporate Governance Report for 2024 is available on IBT´s website, www.ibtherapeutics.com under the section "Investors...
Message from the CEO The scientific literature suggests that benign bacteria of the type found in IBT's drug product IBP-9414 can positively affect the...
IBT received results in August from the largest ever randomized clinical trial in premature infants. During the fall, IBT has continued to review the phase...

Subscribe to our press releases